[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Gadducci A, Cavazzana A, Cosio S, DI Cristofano C, Tana R, Fanucchi A, Teti G, Cristofani R, Genazzani AR: Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res; 2009 May;29(5):1715-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer.
  • The aim of this retrospective study was to assess the predictive value of different clinicopathological variables (patient age, tumour size, FIGO grade, myometrial invasion, lymph-vascular space involvement [LVSI], invasion margins, peri-tumour phlogistic infiltrate and mitotic activity) for the risk of distant haematogenous recurrences in patients with endometrioid-type stage Ib-II endometrial cancer.
  • Between August 1990 and April 2005, 259 patients had undergone laparotomy, peritoneal washing, total abdominal hysterectomy and bilateral salpingo-oophorectomy, with or without pelvic +/- para-aortic lymphadenectomy for endometrioid-type endometrial cancer.
  • Thirty-six (13.9%) patients had developed recurrent disease after a median time of 17 months (range, 2-128 months).
  • This study assessed 12 patients with FIGO stage Ib-II disease who had developed distant haematogenous recurrences and 20 randomly chosen control patients with FIGO stage Ib-II disease who had remained recurrence-free after a median follow-up of 52 months (range, 37-66 months).
  • Adjuvant therapy had been: no further treatment in 15 patients, external pelvic irradiation in 14 patients, adjuvant external pelvic irradiation plus brachytherapy in 2 patients and platinum-based chemotherapy followed by external pelvic irradiation in 1 patient.
  • % versus 20.0%, p=0.0022) was found in the patients who had developed distant haematogeneous metastases compared to the recurrence-free women.
  • Patients with these pathological findings should be enrolled in randomised trials designed to assess the role of adjuvant chemotherapy alone or combined with sequential and/or concomitant external pelvic irradiation.
  • [MeSH-major] Endometrial Neoplasms / pathology. Myometrium / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Invasiveness. Recurrence. Retrospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443392.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Wu HM, Lai CH, Huang HY, Wang HS, Soong YK: A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer. Chang Gung Med J; 2008 Jan-Feb;31(1):102-6
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer.
  • Magnetic resonance imaging (MRI) revealed endometrial lesions without myometrium invasion and no pelvic lymph node enlargement.
  • Fertility-preserving medical therapy with megestrol acetate for 1 year and subsequent assisted reproductive treatment (ART) were performed.
  • On the basis of these observations and the low malignant potential of well-differentiated endometrial carcinoma, fertility-preserving treatment using Megace therapy was suggested.
  • In this case, recurrence occurred after the completion of Megace therapy and three failed attempts at artificial insemination by the husband (AIH).
  • Another course of Megace therapy was administered due to her desire for children.
  • A successful pregnancy occurred after long-term medical treatment and IVF-ET.
  • [MeSH-major] Adenocarcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Fertilization in Vitro. Megestrol Acetate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Twins

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419059.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


3. Oguz S, Sargin A, Aytan H, Kelekci S, Dumanli H: Doppler study of myometrium in invasive gestational trophoblastic disease. Int J Gynecol Cancer; 2004 Sep-Oct;14(5):972-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doppler study of myometrium in invasive gestational trophoblastic disease.
  • OBJECTIVE: In this prospective study, we aimed to assess the prognostic and diagnostic role of color Doppler flow of myometrium in patients with invasive gestational trophoblastic disease (GTD).
  • METHODS: Thirty-seven patients, who were enrolled in the study with invasive mole, were assessed with the help of transvaginal color Doppler ultrasound before and after chemotherapy.
  • RESULTS: Thirty patients of 37 were treated with the help of single-agent chemotherapy--methotrexate (mtx).
  • When the depth and the width of the myometrial invasion increase and when there is a low diastolic/systolic ratio, the number of courses and the need for combination of chemotherapy increase.
  • [MeSH-major] Gestational Trophoblastic Disease / pathology. Gestational Trophoblastic Disease / ultrasonography. Myometrium / pathology. Myometrium / ultrasonography. Ultrasonography, Doppler, Color. Uterine Neoplasms / pathology. Uterine Neoplasms / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dactinomycin / administration & dosage. Diagnosis, Differential. Female. Humans. Methotrexate / therapeutic use. Middle Aged. Neoplasm Invasiveness. Prognosis. Prospective Studies. Sensitivity and Specificity. Vagina / ultrasonography

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361211.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 1CC1JFE158 / Dactinomycin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Lyman MD, Neuhauser TS: Precursor T-cell acute lymphoblastic leukemia/lymphoma involving the uterine cervix, myometrium, endometrium, and appendix. Ann Diagn Pathol; 2002 Apr;6(2):125-8
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor T-cell acute lymphoblastic leukemia/lymphoma involving the uterine cervix, myometrium, endometrium, and appendix.
  • This report presents a case of precursor T-cell acute lymphoblastic leukemia/lymphoma (ALL) involving the uterine cervix, myometrium, endometrium, and appendix.
  • The patient was a 38-year-old woman with a history of ALL who had been in remission for 4 years following chemotherapy.
  • The patient was again treated with chemotherapy but her disease did not respond.
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Fatal Outcome. Female. Humans. Hysterectomy. Immunohistochemistry. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12004362.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


5. Su WH, Wang PH, Chang SP: Successful treatment of a persistent mole with myometrial invasion by direct injection of methotrexate. Eur J Gynaecol Oncol; 2001;22(4):283-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a persistent mole with myometrial invasion by direct injection of methotrexate.
  • For patients with persistent or invasive gestational trophoblastic disease (GTD), systemic injection of chemotherapy is the treatment of choice if fertility is to be preserved.
  • To prevent serious adverse effects after systemic use and possibly achieve better effects, direct local injection of chemotherapy into the tumor site, especially when in the myometrium, seems a reasonable alternative.
  • During the same period, a well-defined invasive complex with multiple vesicles in the myometrium was documented using transvaginal ultrasound (TVUS).
  • An obvious shrinkage of the mass and declining beta-hCG level were demonstrated after the procedure.
  • Since no identical cases were found in our review of the English literature, more cases and similar regimens are needed to establish the safety and efficacy of this procedure.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Hydatidiform Mole / drug therapy. Methotrexate / administration & dosage. Myometrium / pathology. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chorionic Gonadotropin, beta Subunit, Human / analysis. Female. Humans. Injections, Intralesional. Neoplasm Invasiveness. Neoplasm, Residual. Pregnancy. Vacuum Curettage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11695810.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Chorionic Gonadotropin, beta Subunit, Human; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Gründker C, Völker P, Griesinger F, Ramaswamy A, Nagy A, Schally AV, Emons G: Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol; 2002 Sep;187(3):528-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These receptors can be used for targeted chemotherapy with cytotoxic luteinizing hormone-releasing hormone analogs such as AN-152, in which doxorubicin is linked to [D-Lys(6)]luteinizing hormone-releasing hormone.
  • Luteinizing hormone-releasing hormone receptor expression in tumors and specimens of human reproductive (n = 5) and nonreproductive (n = 15) normal tissues and in hematopoietic stem cells were analyzed with reverse transcriptase-polymerase chain reaction and radioligand binding assay.
  • RESULTS: The tumor volumes of luteinizing hormone-releasing hormone receptor-positive HEC-1B and NIH:OVCAR-3 cancers were reduced significantly (P <.001) 1 week after treatment with AN-152 at 700 nmol/20 g or at 300 nmol/20 g.
  • Treatment with doxorubicin arrested tumor growth but did not reduce tumor volume.
  • Normal human nonreproductive tissues, hematopoietic stem cells, and vaginal tissue did not express luteinizing hormone-releasing hormone receptors, but luteinizing hormone-releasing hormone receptors were found in the ovary, fallopian tube, cervix, endometrium, and myometrium.
  • AN-152 could be considered for targeted chemotherapy in patients with ovarian or endometrial cancers.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Endometrial Neoplasms / drug therapy. Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Animals. Binding Sites. Female. Humans. Mice. Mice, Nude. Neoplasm Transplantation. RNA, Messenger / analysis. Receptors, LHRH / drug effects. Receptors, LHRH / genetics. Receptors, LHRH / metabolism. Transplantation, Heterologous. Tumor Cells, Cultured


7. Wu TI, Hsu KH, Huang HJ, Hsueh S, Chou HH, Tsai CS, Ho KC, Chao A, Chang TC, Lai CH: Prognostic factors and adjuvant therapy in uterine carcinosarcoma. Eur J Gynaecol Oncol; 2008;29(5):483-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and adjuvant therapy in uterine carcinosarcoma.
  • PURPOSE OF INVESTIGATION: The objective of this retrospective study was to investigate prognostic variables and impact of adjuvant therapy in uterine carcinosarcoma.
  • Stratified analyses demonstrated a monotonic trend of chemotherapy or chemoradiation to decrease death.
  • CONCLUSIONS: Our results suggested that age and depth of myometrial invasion were significant prognostic factors, and chemotherapy or chemoradiation seemed to be beneficial for uterine carcinosarcoma.
  • [MeSH-major] Carcinosarcoma / mortality. Carcinosarcoma / therapy. Uterine Neoplasms / mortality. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051818.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


8. Ruvalcaba-Limón E, Cantú-de-León D, León-Rodríguez E, Cortés-Esteban P, Serrano-Olvera A, Morales-Vásquez F, Sosa-Sánchez R, Poveda-Velasco A, Crismatt-Zapata A, Santillán-Gómez A, Aguilar-Jiménez C, Alanís-López P, Alfaro-Ramírez P, Alvarez-Avitia MA, Aranda-Flores CE, Arias-Ceballos JH, Arrieta-Rodríguez O, Barragán-Curiel E, Botello-Hernández D, Brom-Valladares R, Cabrera-Galeana PA, Cantón-Romero JC, Capdeville-García D, Cárdenas-Sánchez J, Castorena-Roji G, Cepeda-López FR, Cervantes-Sánchez G, Cetina-Pérez Lde C, Coronel-Martínez JA, Cortés-Cárdenas SA, Cruz-López JC, de la Garza-Salazar JG, Díaz-Romero C, Dueñas-González A, Valle-Solís AE, Escudero-de los Ríos P, Flores-Alvarez E, García-Matus R, Gerson-Cwilich R, González-Enciso A, González-de-León C, Guevara-Torres AG, Herbert-Núñez GS, Hernández-Hernández C, Hernández-Hernández DM, Isla-Ortiz D, Jesús-Sandoval R, Jiménez-Cervantes C, Kuri-Exsome R, López-Obispo JL, Maffuz-Aziz A, Martínez-Barrera LM, Medina-Castro JM, Montalvo-Esquivel G, Mora-Aguilar VH, Morales-Palomares MA, Morán-Mendoza A, Morgan-Villela G, Mota-García A, Muñoz-González DE, Murillo-Cruz DA, Novoa-Vargas A, Ochoa-Carrillo FJ, Oñate-Ocaña LF, Ortega-Rojo A, Palacios-Martínez AG, Palomeque-López A, Pérez-Montiel MD, Quijano-Castro F, Rivera-Rivera S, Rivera-Rubí LM, Robles-Flores JU, Rodríguez-Trejo A, Salas-Gonzáles E, Silva JA, Solorza-Luna G, Souto-del-Bosque R, Tirado-Gómez LL, Torrescano-González S, Torres-Lobatón A, Trejo-Durán E, Villavicencio-Valencia V, Gallardo-Rincón D, Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México: [The first Mexican consensus of endometrial cancer. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México]. Rev Invest Clin; 2010 Nov-Dec;62(6):583, 585-605
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GICOM collaborative group under the auspice of different institutions have made the following consensus in order to make recommendations for the management of patients with this type of neoplasm.
  • RESULTS: Screening should be performed women at high risk (diabetics, family history of inherited colon cancer, Lynch S. type II).
  • Diagnosis is made by histerescopy-guided biopsy.
  • Total abdominal hysterectomy, bilateral salpingo oophorectomy, pelvic and para-aortic lymphadenectomy should be performed except in endometrial histology grades 1 and 2, less than 50% invasion of the myometrium without evidence of disease out of the uterus.
  • Adjuvant treatment after surgery includes radiation therapy to the pelvis, brachytherapy, and chemotherapy.
  • Patients with Stages III and IV should have surgery with intention to achieve optimal cytoreduction because of the impact on survival (51 m vs. 14 m), the treatment of recurrence can be with surgery depending on the pattern of relapse, systemic chemotherapy or hormonal therapy.
  • Multidisciplinary treatment impacts on survival and local control of the disease, including surgery, radiation therapy and chemotherapy, hormonal treatment is reserved to selected cases of recurrence.
  • This is the first attempt of a Mexican Collaborative Group in Gynecology to give recommendations is a special type of neoplasm.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnostic Imaging. Estrogen Antagonists / adverse effects. Estrogen Replacement Therapy / adverse effects. Estrogens / adverse effects. Evidence-Based Medicine. Female. Humans. Hysterectomy / methods. Laparoscopy. Lymph Node Excision. Mass Screening. Mexico. Neoplasm Staging / methods. Radiotherapy, Adjuvant. Risk Factors. Salvage Therapy. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21416918.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] spa
  • [Publication-type] Consensus Development Conference; English Abstract; Journal Article; Practice Guideline
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Estrogen Antagonists; 0 / Estrogens; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


9. Koo HL, Choi J, Kim KR, Kim JH: Pure non-gestational choriocarcinoma of the ovary diagnosed by DNA polymorphism analysis. Pathol Int; 2006 Oct;56(10):613-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-gestational choriocarcinoma has been found to be resistant to single-agent chemotherapy and has a worse prognosis than gestational choriocarcinoma, but it is difficult to distinguish the two types by routine histological examination.
  • All tested microsatellite markers had identical DNA profiles with the same allelic sizes between the tumor and the myometrium of the patient, who was homozygous for three markers (BAT26, BAT25 and D17S250) and heterozygous for four (D2S123, D18S57, DCC and D18S58), supporting non-gestational origin.
  • The patient has no evidence of disease 17 months after surgery and four cycles of combination chemotherapy.
  • [MeSH-major] Choriocarcinoma, Non-gestational / diagnosis. DNA, Neoplasm / genetics. Ovarian Neoplasms / diagnosis. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984618.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


10. Hurst SA, Hartzfeld KM, Del Priore G: Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer. Fertil Steril; 2008 Mar;89(3):724.e1-3
MedlinePlus Health Information. consumer health - Female Infertility.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer.
  • OBJECTIVE: We report a case of endometrial cancer treated by fertility-preserving P therapy, who subsequently presented with an abnormal magnetic resonance imaging (MRI) of the myometrium despite normal endometrial biopsies.
  • PATIENT(S): A 31-year-old patient with grade 1, stage I endometrial cancer presented for treatment with fertility-preserving P therapy.
  • INTERVENTION(S): Progestogen therapy, laparoscopic-assisted vaginal hysterectomy, oophoropexy, and assisted reproductive techniques (ART) and surrogate.
  • RESULT(S): Eight years after initial diagnosis, the patient remains cancer free and has conceived by surrogate reproductive techniques.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Fertility. Infertility, Female / prevention & control. Megestrol Acetate / therapeutic use. Myometrium / pathology. Neoplasm Recurrence, Local. Progestins / therapeutic use
  • [MeSH-minor] Adult. Dilatation and Curettage. Female. Humans. Hysterectomy, Vaginal. Hysteroscopy. Laparoscopy. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Staging. Ovariectomy. Pregnancy. Quality of Life. Reproductive Techniques, Assisted. Surrogate Mothers. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17570366.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Progestins; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


11. Southcott BM: Carcinoma of the endometrium. Drugs; 2001;61(10):1395-405
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence rises with age and is significantly increased when there is exposure to unopposed estrogen, including hormone replacement therapy (HRT).
  • Transvaginal ultrasound and pipelle or hysteroscopy endometrial biopsies are tending to replace the traditional dilation and curettage in establishing a diagnosis.
  • Prognostic factors include the histological grade, the depth of invasion of the myometrium, the presence or absence of lymph-vascular space invasion and involved regional nodes, tumour volume, and the presence or absence of involvement of the cervix.
  • The pelvis is a major anatomical site at risk of recurrence, and since cytotoxic chemotherapy and hormone therapies have limited effectiveness, radiotherapy is the adjuvant therapy of choice where adverse prognostic factors are present.
  • A move towards more radical surgery--the addition of lymphadenectomy with a total abdominal hysterectomy and bi-lateral salpingo oophorectomy, may modify the value of adjuvant therapy and has highlighted the need to demonstrate the exact place of post operative radiotherapy in the management of endometrial cancer.
  • Spread outside the pelvis to para-aortic nodes may still be salvaged with local irradiation, but systemic disease is incurable and treatment is largely palliative including consideration of local irradiation, hormone therapy or chemotherapy for symptomatic relief.
  • As reliable techniques for diagnosis are refined an even larger proportion of patients will be diagnosed with early disease.
  • This, together with the development of new cytotoxic agents and sophisticated radiotherapy techniques to reduce normal tissue morbidity, will require the establishment of further clinical trials to refine optimal management.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Hormone Replacement Therapy / adverse effects. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Salvage Therapy. Tamoxifen / adverse effects

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1994 Jul;84(1):12-6 [8008305.001]
  • [Cites] Obstet Gynecol. 1979 Jul;54(1):85-9 [450367.001]
  • [Cites] Gynecol Oncol. 1974 Aug;2(2-3):368-76 [4616883.001]
  • [Cites] Am J Dermatopathol. 1996 Feb;18(1):94-8 [8721599.001]
  • [Cites] Gynecol Oncol. 1999 Jul;74(1):118-22 [10385562.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):570-6 [10027332.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):422-3 [10366471.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Jul;23(7):1025-9 [3665988.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):817-24 [8244810.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):530-3 [9190989.001]
  • [Cites] J Am Podiatr Med Assoc. 1996 Jul;86(7):331-3 [8757485.001]
  • [Cites] Cancer. 1987 May 1;59(9):1665-9 [3828966.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):261-4 [10021312.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1131-7 [10393721.001]
  • [Cites] Hum Reprod. 1999 May;14(5):1381-3 [10325299.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Nov;4(6):373-6 [1463690.001]
  • [Cites] Acta Obstet Gynecol Scand. 1986;65(3):247-55 [3739631.001]
  • [Cites] Br J Cancer. 1984 Nov;50(5):687-92 [6498067.001]
  • [Cites] Acta Oncol. 1990;29(2):203-9 [2185804.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(5):425-36 [8253106.001]
  • [Cites] Clin Radiol. 1985 Nov;36(6):619-23 [4064547.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(2):87-9 [10376419.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):407-11 [10366468.001]
  • [Cites] J Chronic Dis. 1987;40 Suppl 2:59S-69S [3667868.001]
  • [Cites] Br J Hosp Med. 1995 Sep 6-19;54(5):198-201 [8528525.001]
  • [Cites] Obstet Gynecol. 1981 Nov;58(5):590-5 [7301235.001]
  • [Cites] Histopathology. 1999 Jan;34(1):51-5 [9934584.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(2):156-9 [10376438.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(6):520-1 [8971533.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1999;11(4):252-4 [10473722.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(1):8-12 [10422671.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1985;2(3):125-35 [4068799.001]
  • [Cites] Eur J Gynaecol Oncol. 1997;18(6):492-4 [9443018.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):320-7 [9010105.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jul;157(1):35-40 [3605266.001]
  • [Cites] Am J Clin Nutr. 1987 Jan;45(1 Suppl):283-9 [3799518.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jan;156(1):20-3 [3799753.001]
  • [Cites] Strahlenther Onkol. 1991 Jul;167(7):381-6 [1858012.001]
  • [Cites] Maturitas. 1999 Mar 15;31(3):237-40 [10340283.001]
  • [Cites] Obstet Gynecol. 1991 Dec;78(6):1033-8 [1945203.001]
  • [Cites] Mater Med Pol. 1995 Jan-Mar;27(1):23-5 [8569272.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):475-9 [8615657.001]
  • [Cites] Surg Gynecol Obstet. 1971 May;132(5):855-60 [5555407.001]
  • [Cites] Surg Clin North Am. 1991 Oct;71(5):991-1004 [1925858.001]
  • [Cites] Curr Opin Obstet Gynecol. 1994 Feb;6(1):92-7 [8180358.001]
  • [Cites] Lancet. 2000 Sep 9;356(9233):881-7 [11036892.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):419-27 [6999399.001]
  • [Cites] JAMA. 1996 Feb 7;275(5):370-5 [8569016.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1996;8(3):140-5 [8814367.001]
  • (PMID = 11558829.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 57
  •  go-up   go-down


12. Corrado G, Baiocco E, Carosi M, Vizza E: Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report. Fertil Steril; 2008 Nov;90(5):2006.e5-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTION(S): Conservative hysteroscopic resection of the lesion, the surrounding endometrium, and underlying myometrium plus hormone therapy regimen of megestrol acetate (160 mg) daily for 6 months.
  • MAIN OUTCOME MEASURE(S): Failure of the conservative therapy and progression of disease.
  • The patient underwent adjuvant chemotherapy followed by external beam radiation of the pelvis and brachytherapy.
  • CONCLUSION(S): Conservative therapy is feasible in carefully selected young women with endometrial CAH.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / therapy. Endometrial Neoplasms / pathology. Hysteroscopy. Megestrol Acetate / therapeutic use. Precancerous Conditions / therapy
  • [MeSH-minor] Abortion, Spontaneous. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Hysterectomy. Laparoscopy. Neoplasm Staging. Ovariectomy. Ovulation Induction. Pregnancy. Radiotherapy, Adjuvant. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692828.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


13. Torizuka T, Nakamura F, Takekuma M, Kanno T, Ogusu T, Yoshikawa E, Okada H, Maeda M, Ouchi Y: FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nucl Med Commun; 2006 Jun;27(6):481-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Curative tumour resection is possible in superficial invasion (stages IA and IB), while post-surgical chemotherapy or radiation therapy is required in deep invasion (stage IC).
  • We evaluated the value of positron emission tomography with 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG PET) for estimating the myometrial invasion in uterine corpus cancer.
  • [MeSH-major] Fluorodeoxyglucose F18. Myometrium / pathology. Myometrium / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography / methods. Uterine Neoplasms / pathology. Uterine Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Invasiveness. Preoperative Care / methods. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710101.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Lee SJ, Choi YL, Lee EJ, Kim BG, Bae DS, Ahn GH, Lee JH: Increased expression of calpain 6 in uterine sarcomas and carcinosarcomas: an immunohistochemical analysis. Int J Gynecol Cancer; 2007 Jan-Feb;17(1):248-53
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, Capn6 was found to be overexpressed in leiomyosarcomas (LMSs) compared with normal myometrium.
  • Formalin-fixed, paraffin-embedded tissue sections were immunostained with anti-Capn6 domain-II (anti-DII) and anti-Capn6 domain-T (anti-DT) antibodies.
  • All 17 tumors expressed the Capn6 protein; this finding was in contrast to the absence of expression of the Capn6 protein in all of the normal control tissues.
  • There were no significant associations between tumor stage and staining intensity by anti-DII (P= 1.000) or anti-DT (P= 0.576).
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17291261.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.22.- / Calpain
  •  go-up   go-down


15. Wong FC, Pang CP, Tang SK, Tung SY, Leung TW, Sze WK, Cheung KB: Treatment results of endometrial carcinoma with positive peritoneal washing, adnexal involvement and serosal involvement. Clin Oncol (R Coll Radiol); 2004 Aug;16(5):350-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of endometrial carcinoma with positive peritoneal washing, adnexal involvement and serosal involvement.
  • AIMS: To review the treatment results of patients with endometrial carcinoma having positive peritoneal washing (PPW), adnexal involvement, uterine serosal involvement, or all three.
  • MATERIALS AND METHODS: The treatment records of patients who had undergone primary surgery for endometrial cancer without distant metastasis during 1990--2001 at the Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, were reviewed.
  • Two patients with solitary ovarian metastasis received chemotherapy, and one with isolated PPW also received adjuvant hormonal therapy.
  • RESULTS: Among the 28 patients with clinical or pathological node-negative disease (International Federation of Gynecology and Obstetrics [FIGO] stage IIIA), only two patients with solitary ovarian metastases developed recurrence.
  • Five out of the seven patients with lymph-node involvement developed recurrences.
  • Only one patient (3.7%) who had received WART developed grade 4 toxicity.
  • CONCLUSIONS: This study showed that good treatment results could be obtained from patients with stage IIIA endometrial carcinoma without clinical or pathological lymph-node involvement after adjuvant radiotherapy, with acceptable late side-effects.
  • The relative prognostic importance of individual IIIA involvement and the optimal adjuvant treatment remain to be determined.
  • [MeSH-major] Ascitic Fluid / pathology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Myometrium / pathology. Neoplasm Staging. Ovary / pathology. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Review Literature as Topic. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15341439.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Powell JL, Stinson JA, Connor GP, Shiro BS, Mattison M: Squamous cell carcinoma arising in a dermoid cyst of the ovary. Gynecol Oncol; 2003 Jun;89(3):526-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: The case of a 67-year-old woman with stage III squamous cell carcinoma arising in a dermoid cyst of the ovary and extending to the serosa and myometrium of the uterus, pelvic peritoneum, the serosa, and muscularis of the distal ileum and penetrating entirely through the wall of the sigmoid is presented.
  • She was treated with six cycles of Taxol and cisplatin chemotherapy at monthly intervals.
  • This result is encouraging, but the best treatment for advanced cancer of this type has yet to be determined.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Female. Humans. Neoplasm Staging. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12798723.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Coulson LE, Kong CS, Zaloudek C: Epithelioid trophoblastic tumor of the uterus in a postmenopausal woman: a case report and review of the literature. Am J Surg Pathol; 2000 Nov;24(11):1558-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report an epithelioid trophoblastic tumor (ETT), a recently delineated type of gestational trophoblastic tumor (GTT), discovered in the uterus of a 66-year-old woman.
  • She had been treated for a hydatidiform mole 17 years previously without chemotherapy.
  • The resected uterus contained a solid/cystic tumor located entirely within the myometrium.
  • Our findings indicate that ETT, like other types of GTT, can occur in postmenopausal women, even years after a gestational event.
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Neoplasm Proteins / analysis. Pregnancy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11075860.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 13
  •  go-up   go-down


18. Tan YT, Zhang X, Lin ZQ, Chen Q, Wang LJ, Zhang BZ: [Primary clear cell carcinoma of the cervix: report of five cases and review of the literature]. Zhonghua Fu Chan Ke Za Zhi; 2008 Feb;43(2):120-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore the clinical diagnostic and therapeutic characteristics, prognostic factors of patients with primary clear cell carcinoma of the cervix.
  • The primary symptom was mostly irregularly vaginal bleeding (3/5) and clinical type was predominantly (4/5) endophytic growth.
  • All of five patients underwent operation, pathologic examination showed that three patients with infiltration in deep 1/2 myometrium of cervix, and two patients with infiltration in cervix-corpus juncture.
  • All of four patients underwent four courses of chemotherapy with fluorouracil (5-FU) and carboplatin, one patient (stage II a) was added with intracavitary brachytherapy.
  • Pelvic relapse occurred three months after operation and the patient then underwent the second operation, external beam radiotherapy and intracavitary brachytherapy and 8 courses of chemotherapy with paclitaxel (taxol) and carboplatin.
  • Operation combined with chemotherapy with carboplatin and 5-FU or taxol may lead to relatively perfect short-term therapeutical effect.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cervix Uteri / pathology. Female. Fluorouracil / administration & dosage. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Retrospective Studies


19. Toyoda H, Hirai T, Ishii E: Alpha-fetoprotein producing uterine corpus carcinoma: A hepatoid adenocarcinoma of the endometrium. Pathol Int; 2000 Oct;50(10):847-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The postoperative serum AFP value transiently decreased with chemotherapy, however, lung metastases were found and the patient died 12 months following surgery.
  • The resected uterus had a necrotic tumor, 6 x 5 x 4 cm in size, filling the endometrial cavity, characterized by exophytic growth with infiltration in the myometrium.
  • Although the histogenesis remains controversial, we assume the hypothesis that the tumor may arise in the endometrium per se in association with abnormal differentiation of muellerian duct elements.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Fatal Outcome. Female. Humans. Immunoenzyme Techniques. Magnetic Resonance Imaging. Middle Aged. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11107058.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


20. Zanetta G, Gabriele A, Vecchione F, Landoni F, Isimbaldi G: Unusual recurrence of cervical adenosquamous carcinoma after conservative surgery. Gynecol Oncol; 2000 Mar;76(3):409-12
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of less radical procedures for the treatment of early cervical cancers is gaining interest among physicians and young patients.
  • After a polypectomy, a young patient had a diagnosis of stage Ia(2) cervical adenosquamous carcinoma in 1995.
  • In 1998, at the 13th week of gestation, she had a diagnosis of a pelvic mass.
  • The mass was a recurrence of carcinoma involving the myometrium, just underneath the peritoneum.
  • She received chemotherapy postoperatively and remains alive without evidence of disease.
  • With wider acceptance of limited therapeutic approaches we must be prepared for the detection of previously unknown patterns of recurrence and the follow-up modalities must be consequently adapted.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Neoplasm Recurrence, Local. Ovarian Neoplasms / secondary. Pregnancy Complications, Neoplastic. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Conization. Female. Humans. Lymph Node Excision. Neoplasm Invasiveness. Pregnancy. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10684719.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


21. Kinkor Z, Hes O: [Pleomorphic epithelioid/clear cell malignant tumor of the uterus exhibiting both myoid and melanocytic differentiation--leiomyosarcoma or PEComa? A case report and a review of the literature]. Cesk Patol; 2007 Jul;43(3):103-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neoplasm broadly invaded myometrium with no evidence of endometrial cavity involvement.
  • No obvious stigmata of tuberous sclerosis were found and a five months follow-up after chemotherapy indicated no progression of disease.
  • Reviewed is the literature and discussed is the differential diagnosis.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17821838.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


22. Nishimura N, Hachisuga T, Saito T, Kawarabayashi T: Subsequent endometrial carcinoma with adjuvant tamoxifen treatment in Japanese breast cancer patients. Int J Gynecol Cancer; 2001 Jul-Aug;11(4):272-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsequent endometrial carcinoma with adjuvant tamoxifen treatment in Japanese breast cancer patients.
  • This study aimed to detail the clinicopathologic features of endometrial carcinomas that developed in Japanese patients receiving adjuvant tamoxifen treatment for breast cancer patients.
  • Myometrial invasion was limited to the inner half of the myometrium in five cases and involved the outer half in three.
  • The cell types comprised nine endometrioid adenocarcinomas and one serous carcinoma.
  • One patient developed a contralateral breast cancer during tamoxifen treatment.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / etiology. Tamoxifen / adverse effects
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Aged. Asian Continental Ancestry Group. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / etiology. Cystadenocarcinoma, Serous / pathology. Female. Humans. Japan. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11520364.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


23. Thomas L, Bataillard A, Brémond A, Fondrinier E, Fervers B, Achard JL, Lansac J, Bailly C, Hoffstetter S, Basuyau JP, d'Anjou J, Descamps P, Farsi F, Guastalla JP, Laffargue F, Rodier JF, Vincent P, Pigneux J: [Standards, options, and recommendations for the radiotherapy of patients with endometrial cancer. FNCLCC (National Federation of Cancer Campaign Centers) and CRLCC (Regional Cancer Campaign Centers)]. Cancer Radiother; 2001 Apr;5(2):163-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Standards, Options et Recommandations pour la radiothérapie des patientes atteintes de cancer de l'endomètre.
  • 1) For grade 1 and 2 stage IA tumours, follow-up alone is standard as additional treatment.
  • For grade 3, stage IB tumours and stage IC disease, there are two treatment options: external pelvic radiotherapy with a brachytherapy boost or vaginal brachytherapy.
  • 2) Treatment for stage II disease can be preoperative when stage II disease has been suggested by a positive endometrial curettage.
  • Postoperative vaginal brachytherapy is given for stage IIA tumours if the penetration of the myometrium is less than 50% or if the tumour is grade 1 or 2.
  • 3) After surgery, for stage IIIA disease, either external pelvic radiotherapy or abdomino-pelvic radiotherapy is indicated, along with medical treatment in certain patients.
  • For stage IIIC tumours, standard treatment is external (pelvic or pelvic and para-aortic) radiotherapy followed or not by a brachytherapy boost.
  • 4) Standard treatment for inoperable stage I and II disease is external radiotherapy and brachytherapy.
  • For patients with inoperable stage III or IV disease, treatment is often symptomatic, combining external radiotherapy and medical treatment.
  • [MeSH-minor] Brachytherapy / adverse effects. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma / radiotherapy. Carcinoma / surgery. Cesium Radioisotopes / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Hysterectomy. Indium Radioisotopes / therapeutic use. Lymphatic Irradiation / adverse effects. Lymphatic Metastasis / radiotherapy. Neoplasm Staging. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / radiotherapy. Peritoneal Neoplasms / secondary. Postoperative Period. Preoperative Care. Radiation Injuries / etiology. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, High-Energy / adverse effects. Radium / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11355582.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Guideline; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cesium Radioisotopes; 0 / Indium Radioisotopes; W90AYD6R3Q / Radium
  •  go-up   go-down


24. Hauth E, Libera H, Kimmig R, Forsting M: [MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer patients in tamoxifen therapy]. Rofo; 2006 Mar;178(3):316-23
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer patients in tamoxifen therapy].
  • [Transliterated title] Magnetresonanztomographie (MRT) des Beckens zur Beurteilung des Endometriums unter Tamoxifentherapie.
  • PURPOSE: The purpose of the study was to determine the value of MR imaging of the pelvis in the diagnostic work-up of the endometrium in breast cancer patients in tamoxifen therapy.
  • The volume of the uterus and cervix and the maximal thickness of the endometrium, junctional zone and myometrium of the uterus were determined and compared to the confidence interval of the parameters in healthy women.
  • CONCLUSION: MR imaging might be helpful in the diagnosis of endometrium pathologies during tamoxifen therapy.
  • Therefore, MR imaging of the pelvis could be used as a diagnostic tool in the follow-up diagnosis of the endometrium in breast cancer patients in tamoxifen therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Cervix Uteri / drug effects. Endometrial Neoplasms / diagnosis. Endometrium / drug effects. Endometrium / pathology. Magnetic Resonance Imaging / methods. Polyps / diagnosis. Tamoxifen / adverse effects. Tamoxifen / therapeutic use. Uterus / drug effects
  • [MeSH-minor] Aged. Confidence Intervals. Data Interpretation, Statistical. Endometrial Hyperplasia / chemically induced. Endometrial Hyperplasia / diagnosis. Endometrial Hyperplasia / pathology. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiology Information Systems. Time Factors


25. Shozu M, Sumitani H, Segawa T, Yang HJ, Murakami K, Inoue M: Inhibition of in situ expression of aromatase P450 in leiomyoma of the uterus by leuprorelin acetate. J Clin Endocrinol Metab; 2001 Nov;86(11):5405-11
Hazardous Substances Data Bank. LEUPROLIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we demonstrated that leuprorelin acetate, a GnRH agonist widely used for treatment of uterine leiomyoma by down-regulation of pituitary-ovarian function, suppressed the expression of aromatase P450 (an estrogen synthetase) in leiomyoma cells.
  • Quantitative RT-PCR revealed that in women receiving no medication uterine leiomyomas express aromatase P450 mRNA at levels 20 times higher than that in the surrounding myometrium.
  • Leuprorelin acetate treatment (1.88 mg every 4 wk, sc injection) for 12-24 wk reduced the expression of aromatase P450 mRNA in leiomyoma tissue as well as in the myometrium, to approximately one tenth of that in the myometrium of untreated women.
  • The addition of various concentrations of E2 did not affect the aromatase activity of leiomyoma cells, suggesting that deprivation of circulating (ovarian) estrogen is not a cause of decreased expression of aromatase during leuprorelin acetate therapy.
  • On the other hand, 8-d treatment with leuprorelin acetate (100 nmol/liter) reduced dexamethasone + IL-1beta-induced activity and a mRNA level of aromatase by 28% and 42%, respectively.
  • These results indicated that leuprorelin acetate inhibits the expression of aromatase P450 in leiomyoma cells, which contributes to the rapid regression of leiomyoma during leuprorelin acetate therapy.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Aromatase / biosynthesis. Gene Expression Regulation, Neoplastic / drug effects. Leiomyoma / enzymology. Leuprolide / pharmacology. Uterine Neoplasms / enzymology
  • [MeSH-minor] Blotting, Western. Cell Division / drug effects. Depression, Chemical. Estradiol / pharmacology. Estrogens / physiology. Female. Gene Expression Regulation, Enzymologic / drug effects. Gonadotropin-Releasing Hormone / agonists. Humans. In Vitro Techniques. Menopause / physiology. Neoplasm Proteins / biosynthesis. RNA, Messenger / biosynthesis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11701714.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 33515-09-2 / Gonadotropin-Releasing Hormone; 4TI98Z838E / Estradiol; EC 1.14.14.1 / Aromatase; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


26. Pointreau Y, Bernadou G, Denis F, Barillot I: [Endometrial cancer]. Cancer Radiother; 2010 Nov;14 Suppl 1:S154-60
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is the reference for a precise FIGO staging who guide adjuvant treatment.
  • Tumor extension, grade, myometrium invasion and involved lymph nodes will be discriminating in therapeutic strategy.
  • The management of stages I and II has been recently amended by ESMO, who proposed surveillance, brachytherapy, and radiation therapy followed by brachytherapy for respectively low, intermediate and high risk groups.
  • Locally advanced stages represent a heterogeneous population in which surgery should be proposed if it is feasible then followed by radiotherapy and/or chemotherapy.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Brachytherapy / methods. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Postmenopause. Prognosis. Radiotherapy / adverse effects. Radiotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21129659.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement